https://nypost.com/2024/08/05/us-ne...d-bear-cub-before-dumping-it-in-central-park/ Bear market for health?
This prediction might be an exaggeration but I wouldn’t want to be the test subject. “The U.K. government’s PHE Vaccine Surveillance Report reveals that doubly vaccinated 40-70-year-olds have lost 40% of their immune system capability compared to unvaccinated people. Their immune systems are deteriorating at around 5% per week (between 2.7% and 8.7%). If this continues then 30-50-year-olds will have 100% immune system degradation, zero viral defence by Christmas and all doubly vaccinated people over 30 will have lost their immune systems by March next year.”
chatgpt on saMRNA jabs: Self-amplifying mRNA (saRNA) vaccines hold significant promise, but they also come with several potential drawbacks and challenges that need careful consideration. Here are the primary negatives associated with saRNA vaccines: ### 1. **Enhanced Risk of Immune Overactivation** - **Immune Response to Replicase Proteins:** Self-amplifying RNA vaccines rely on the addition of viral replicase enzymes (often from alphaviruses). These enzymes can trigger **unintended immune responses**, as the host immune system may recognize these viral elements as foreign and mount a strong inflammatory reaction. - **Potential for Cytokine Storm:** The amplification process leads to increased antigen production, which, while boosting the immune response, can also increase the risk of **overactive immune responses** like a cytokine storm. This is particularly concerning for individuals with preexisting inflammatory or autoimmune conditions. ### 2. **Safety and Control Issues** - **Uncontrolled Replication Risk:** Although the RNA replication is designed to be self-limiting, there is still a theoretical risk of **uncontrolled replication** if the mechanism malfunctions. This could lead to excessive antigen production, resulting in adverse effects or toxicity. - **Side Effects from High Antigen Load:** With increased and prolonged antigen expression, the side effects might be more severe than those seen with traditional mRNA vaccines. Symptoms such as **fever, fatigue, and muscle pain** could be more intense due to the extended duration of antigen exposure. ### 3. **Delivery Challenges** - **Lipid Nanoparticles (LNPs) Limitations:** saRNA vaccines require efficient delivery systems, typically using lipid nanoparticles. However, LNPs can trigger their own set of immune reactions, leading to **local inflammation** or **allergic responses** in some individuals. Additionally, optimizing LNPs to safely deliver larger RNA constructs (as saRNA is larger than standard mRNA) is challenging. - **Instability of saRNA:** Self-amplifying RNA is less stable than conventional mRNA, making it more prone to **degradation**. This can limit its shelf life and necessitates strict cold-chain storage conditions, complicating distribution. ### 4. **Limited Understanding of Long-Term Effects** - **Novel Technology:** saRNA vaccines are a relatively new approach, with limited data on long-term safety. The **long-term effects** of introducing replicating RNA constructs into human cells are not fully understood, raising concerns about potential **delayed adverse events** or unforeseen immune reactions. - **Possible Integration Risk (Hypothetical):** Although highly unlikely, there is a theoretical concern about the possibility of RNA integration into the host genome. While current research indicates this is improbable, especially since saRNA does not contain reverse transcriptase, more long-term studies are needed to definitively rule out any such risk. ### 5. **Complex Manufacturing Process** - **Difficulty in Production:** The inclusion of replicase genes makes the saRNA sequence significantly longer than standard mRNA. This larger size complicates the **synthesis, purification, and quality control** processes, potentially increasing production costs and time. - **Batch-to-Batch Variability:** The replicative nature of saRNA could lead to variability in antigen production between individuals or across different batches of the vaccine. This can complicate dosage standardization and efficacy assessments. ### 6. **Potential for Interference with Existing Immunity** - **Pre-existing Immunity to Viral Vectors:** Some saRNA vaccines use sequences derived from viral replicases. If an individual has pre-existing immunity to the virus from which these replicase genes are sourced (e.g., an alphavirus), this could reduce the vaccine’s effectiveness as the body might clear the replicase before sufficient antigen production occurs. - **Autoimmune Concerns:** Given the prolonged antigen presentation and the possible immune response to viral replicase proteins, there may be a heightened risk of **autoimmune reactions**, particularly in individuals with a predisposition to autoimmune disorders. ### Conclusion While self-amplifying RNA vaccines offer a promising path forward for next-generation immunizations, they are not without their challenges. Balancing the amplification benefits against the risks of immune overactivation, potential side effects, and delivery complexities will be key. As the technology advances, ongoing research and clinical trials are needed to address these concerns and optimize the safety profile of saRNA vaccines.